文献速递生殖医学

双重滋养外胚层活检和/或冷冻保存在胚胎植入前遗传学检测中的系统综述与荟萃分析:在诊断需求与伤害风险之间寻求平衡

A systematic review and meta-analysis of double trophectoderm biopsy and/or cryopreservation in PGT: balancing the need for a diagnosis against the risk of harm.
PubMed 文献 · Hum Reprod Update · 2025-01-01

该系统综述与荟萃分析纳入10项研究,比较双重冷冻保存与单次活检(CBC)或双重活检与双重冷冻保存(BCBC)流程与对照单次活检单次冷冻保存(BC)流程的生殖结局。CBC组和BCBC组的活产率、临床妊娠率均低于对照组,流产率高于对照组。作者认为尽管生殖结局较差,这些操作可能仍值得以避免移植受累/非整倍体囊胚,需权衡风险与获益。

要点

  • CBC组每移植活产率低于对照(OR 0.56,95%CI 0.38-0.81,I²=58%)。
  • BCBC组每移植活产率低于对照(OR 0.51,95%CI 0.34-0.77,I²=24%)。
  • CBC组和BCBC组每临床妊娠流产率均高于对照(OR分别为1.68和2.08)。

核心结论

  • 双重活检和/或双重冷冻保存可能降低生殖结局,但作者认为这些操作可能仍值得以避免移植受累/非整倍体囊胚,需针对每对夫妇权衡风险与获益。

研究设计与样本

  • 遵循PRISMA指南检索PubMed、Scopus和Embase至2024年4月的英文同行评议人类原创研究,最终纳入10项研究进行荟萃分析。
  • 证据确定性等级为低至中等。
  • 注册号PROSPERO(ID:CRD42024503678)。

主要发现

  • CBC组每移植活产率低于对照BC组(OR 0.56,95%CI 0.38-0.81,I²=58%;6项研究)。
  • BCBC组每移植活产率低于对照BC组(OR 0.51,95%CI 0.34-0.77,I²=24%;6项研究)。
  • CBC组每移植临床妊娠率低于对照BC组(OR 0.68,95%CI 0.51-0.92,I²=57%;7项研究)。
  • BCBC组每移植临床妊娠率低于对照BC组(OR 0.60,95%CI 0.46-0.78,I²=0%;7项研究)。
  • CBC组每临床妊娠流产率高于对照BC组(OR 1.68,95%CI 1.02-2.77,I²=50%;7项研究);BCBC组也高于对照BC组(OR 2.08,95%CI 1.13-3.83,I²=28%;7项研究)。

关键数值与推荐

  • 报告冷冻存活率以及妊娠和围产结局的研究中,这些结局在预期正常范围内。
  • 证据确定性等级范围为低至中等。

临床怎么用

  • 作者认为尽管双重活检和/或双重冷冻保存可能导致较差的生殖结局,这些操作可能仍值得以避免移植受累/非整倍体囊胚,需针对每对夫妇权衡风险与获益。
  • 作者提出改进遗传技术、标准化实验室流程、操作者活检和冷冻保存熟练度以及持续监测性能对于最小化不确定诊断和额外胚胎操作的推定影响至关重要。

局限性

  • 证据确定性等级为低至中等。
  • 各结局的异质性I²值分别为58%、24%、57%、0%、50%和28%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To prevent the transfer of embryos affected by monogenic conditions and/or chromosomal defects, preimplantation genetic testing (PGT) requires trophectoderm biopsy and cryopreservation. In 2-6% of biopsies, the diagnosis may be inconclusive due to DNA amplification failure or low-quality results. In these cases, a round of re-warming, re-biopsy, and re-cryopreservation is required to obtain a genetic diagnosis. In other cases, when the IVF centre starts providing PGT and/or when the patients develop an indication because of multiple failures, miscarriages or the birth of an affected child after IVF, cryopreserved untested embryos may be warmed, biopsied, and then re-vitrified. However, it is still unclear whether multiple manipulations may reduce reproductive outcomes after PGT. OBJECTIVE AND RATIONALE: This study aimed at conducting a systematic review to investigate the available evidence on the safety of double biopsy and/or double cryopreservation-warming and provide recommendations in this regard. We performed meta-analyses of the differences in the reproductive outcomes (live birth per embryo transfer [LBR per ET], clinical pregnancy rate per ET [CPR per ET], and miscarriage rate per clinical pregnancy [MR per CP]) in double cryopreservation and single biopsy (CBC) or double biopsy and double cryopreservation (BCBC) flows vs the control single biopsy and single cryopreservation (BC) flow. Cryo-survival rates before ET and gestational and perinatal outcomes were also reported. SEARCH METHODS: PRISMA guidelines were followed to gather all available information from the literature (PubMed, Scopus, and Embase). We used Medical Subject Headings (MeSH) terms and a list of specific keywords relevant for the study question. We searched for original studies in humans, published in peer-reviewed journals in English up to April 2024. Four independent authors assessed the articles for inclusion. One included paper was retrieved from another source. OUTCOMES: A total of 4219 records were identified, and 10 studies were included in the meta-analysis. Certainty of evidence level ranged from low to moderate. Both the CBC and BCBC groups showed reduced reproductive outcomes compared to the control (BC). Specifically, live birth rates per embryo transfer were lower in the CBC group (OR: 0.56, 95% CI: 0.38-0.81, I2 = 58%; six studies) and the BCBC group (OR: 0.51, 95% CI: 0.34-0.77, I2 = 24%; six studies). CPR per ET were also lower in the CBC group (OR: 0.68, 95% CI: 0.51-0.92, I2 = 57%; seven studies) and the BCBC group (OR: 0.60, 95% CI: 0.46-0.78, I2 = 0%; seven studies). Additionally, MR per CPs were higher in both the CBC group (OR: 1.68, 95% CI: 1.02-2.77, I2 = 50%; seven studies) and the BCBC group (OR: 2.08, 95% CI: 1.13-3.83, I2 = 28%; seven studies). Cryo-survival as well as gestational and perinatal outcomes were within the expected norms in the studies reporting them. WIDER IMPLICATIONS: Improved genetic technologies, standardization of laboratory protocols, operators' proficiency with biopsy and cryopreservation, and continuous monitoring of the performance are essential to minimize inconclusive diagnoses and the putative impact of additional embryo manipulations. Although poorer reproductive outcomes might result from double biopsy and/or double cryopreservations, these practices may still be worthwhile to avoid transferring affected/aneuploid blastocysts. Therefore, the risks must be weighed against the potential benefits for each specific couple. REGISTRATION NUMBER: PROSPERO (ID: CRD42024503678).

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Li Piani L, Petrone P, Brutto M, et al. A systematic review and meta-analysis of double trophectoderm biopsy and/or cryopreservation in PGT: balancing the need for a diagnosis against the risk of harm. Hum Reprod Update. 2025. PMID: 39546333. doi:10.1093/humupd/dmae031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。